171 related articles for article (PubMed ID: 34876272)
41. CAR-T Cell Therapy in Cancer: Tribulations and Road Ahead.
Zhang Q; Ping J; Huang Z; Zhang X; Zhou J; Wang G; Liu S; Ma J
J Immunol Res; 2020; 2020():1924379. PubMed ID: 32411789
[TBL] [Abstract][Full Text] [Related]
42. Reducing infectious complications after allogeneic stem cell transplant.
Bacigalupo A; Metafuni E; Amato V; Marquez Algaba E; Pagano L
Expert Rev Hematol; 2020 Nov; 13(11):1235-1251. PubMed ID: 32996342
[TBL] [Abstract][Full Text] [Related]
43. COVID-19 in patients with cancer: Risks and precautions.
Razavi A; Hamblin MR; Rezaei N
Am J Emerg Med; 2021 Oct; 48():357-360. PubMed ID: 33546958
[TBL] [Abstract][Full Text] [Related]
44. Individual Patient Data Meta-Analysis from 16 Trials for Safety Factors in Cytokine Release Syndrome After CAR-T Therapy in Patients with Non-Hodgkin Lymphoma (NHL) and Acute Lymphoblastic Leukemia.
Li J; Wu Z; Zhao N
Adv Ther; 2019 Oct; 36(10):2881-2894. PubMed ID: 31428935
[TBL] [Abstract][Full Text] [Related]
45. [Requirements for academic production of CAR-T cells in accordance with Good Pharmaceutical Practice (GMP). Guidelines from the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC)].
Deschamps M; Decot V; Giverne C; Pinturaud M; Vaissié A; Parquet N; Olivero S; Anne-Claire M; Bay JO; Yakoub-Agha I; Ferrand C
Bull Cancer; 2020 Jan; 107(1S):S85-S93. PubMed ID: 31547937
[TBL] [Abstract][Full Text] [Related]
46. Nursing Management in Pediatric Patients Undergoing Chimeric Antigen Receptor T (CAR-T) Cell Therapy: A Systematic Literature Review.
Amicucci M; Simioli V; De Cecco V; Orlando L; Ciaralli I; Buccino A; Guidi B; Locatelli G; Palmieri C; Piazzalunga M; Proietti R; Pucci A; Botti S
Semin Oncol Nurs; 2023 Oct; 39(5):151478. PubMed ID: 37544775
[TBL] [Abstract][Full Text] [Related]
47. Infection in the bone marrow transplant recipient.
Walter EA; Bowden RA
Infect Dis Clin North Am; 1995 Dec; 9(4):823-47. PubMed ID: 8747768
[TBL] [Abstract][Full Text] [Related]
48. Management of Chimeric Antigen Receptor (CAR) T-Cell Toxicities: A Review and Guideline for Emergency Providers.
Gupta R; Roach C; Hryniewicki AT; Vilke GM; Shatsky RA; Coyne CJ
J Emerg Med; 2020 Jul; 59(1):61-74. PubMed ID: 32473867
[TBL] [Abstract][Full Text] [Related]
49. [Prevention and treatment of various infections after bone marrow transplantation].
Moriyama Y
Nihon Rinsho; 1990 Sep; 48(9):2028-34. PubMed ID: 2232207
[No Abstract] [Full Text] [Related]
50. [The care process of patient receiving CAR T-cell therapy: Guidelines from the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC)].
Beauvais D; Andrianne C; Aubrun C; Berquier M; Bole S; Caulier A; Courbon C; Delorme J; Fournier I; François G; Jaivenois MF; Le Bars L; Mussot I; Vercasson M; Wallart Brejaud A; Yakoub-Agha I; Lacroix D
Bull Cancer; 2020 Dec; 107(12S):S170-S177. PubMed ID: 32891406
[TBL] [Abstract][Full Text] [Related]
51. [Role of advanced practice nurse within a cellular therapy unit: Guidelines from the Francophone Society of Bone Marrow Transplantation and cellular therapy (SFGM-TC)].
Jezequel T; Cheron N; Ajazi Hub R; Brouillat C; Colonnese E; Desmedt C; Evard S; Hie S; Mourrut C; Vallade D; Bouhier I; Chauvel C; Gandemer V; Mercier L; Yakoub-Agha I
Bull Cancer; 2024 Feb; 111(2S):S50-S66. PubMed ID: 36797127
[TBL] [Abstract][Full Text] [Related]
52. Utilization of CAR T Cell Therapy in Pediatric Patients.
Szenes V; Curran KJ
Semin Oncol Nurs; 2019 Oct; 35(5):150929. PubMed ID: 31526551
[TBL] [Abstract][Full Text] [Related]
53. Immunotherapy Using Chimeric Antigen Receptor-Engineered T Cells: A Novel Cellular Therapy with Important Implications for the Clinical Laboratory.
Thibodeaux SR; Milone MC
Clin Chem; 2019 Apr; 65(4):519-529. PubMed ID: 30593467
[TBL] [Abstract][Full Text] [Related]
54. Chimeric antigen receptor T cell immunotherapy for multiple myeloma: A review of current data and potential clinical applications.
Susanibar Adaniya SP; Cohen AD; Garfall AL
Am J Hematol; 2019 May; 94(S1):S28-S33. PubMed ID: 30730071
[TBL] [Abstract][Full Text] [Related]
55. Preclinical Models in Chimeric Antigen Receptor-Engineered T-Cell Therapy.
Siegler EL; Wang P
Hum Gene Ther; 2018 May; 29(5):534-546. PubMed ID: 29390873
[TBL] [Abstract][Full Text] [Related]
56. Chimeric antigen receptor T-cells safety: A pharmacovigilance and meta-analysis study.
Dolladille C; Ederhy S; Ezine E; Choquet S; Nguyen LS; Alexandre J; Moslehi JJ; Dechartres A; Salem JE
Am J Hematol; 2021 Sep; 96(9):1101-1111. PubMed ID: 34057232
[TBL] [Abstract][Full Text] [Related]
57. [Indications and follow-up for autologous hematopoietic stem cell transplantation in multiple sclerosis: Guidelines from the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC) in association with the Francophone Society of Multiple Sclerosis].
Zephir H; Puyade M; Gueguen A; Michel L; Terriou L; Dive D; Laureys G; Mathey G; Labauge P; Marjanovic Z; Pugnet G; Badoglio M; Lansiaux P; Yakoub-Agha I; Béguin Y; Farge D
Bull Cancer; 2019 Jan; 106(1S):S92-S101. PubMed ID: 30527815
[TBL] [Abstract][Full Text] [Related]
58. Management of cytokine release syndrome and neurotoxicity in chimeric antigen receptor (CAR) T cell therapy.
Acharya UH; Dhawale T; Yun S; Jacobson CA; Chavez JC; Ramos JD; Appelbaum J; Maloney DG
Expert Rev Hematol; 2019 Mar; 12(3):195-205. PubMed ID: 30793644
[TBL] [Abstract][Full Text] [Related]
59. [Importance of prevention of infectious complications in pediatric hematologic-oncologic patients].
Fleischhack G; Simon A
Klin Padiatr; 2001 Sep; 213 Suppl 1():A5-8. PubMed ID: 11577360
[TBL] [Abstract][Full Text] [Related]
60. Programmable and multi-targeted CARs: a new breakthrough in cancer CAR-T cell therapy.
Tahmasebi S; Elahi R; Khosh E; Esmaeilzadeh A
Clin Transl Oncol; 2021 Jun; 23(6):1003-1019. PubMed ID: 32997278
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
